<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02435693</url>
  </required_header>
  <id_info>
    <org_study_id>pc</org_study_id>
    <nct_id>NCT02435693</nct_id>
  </id_info>
  <brief_title>Pharmaceutical Care Program for Type 2 Diabetes Mellitus</brief_title>
  <acronym>pcp</acronym>
  <official_title>Evaluation of Pharmaceutical Care Program for Type 2 Diabetes Mellitus in Dhule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TABREJ MUJAWAR</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>R. C. Patel Institute of Pharmaceutical Education &amp; Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of Pharmaceutical Care Program for Type 2 diabetes mellitus in Dhule

      Objectives:-

        1. To evaluate Pharmaceutical care program in Type2 diabetics.

        2. To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with
           Type-2 Diabetes Mellitus.

        3. To study the prevalence of Type2 diabetics cases in Dhule.

        4. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2
           diabetics.

        5. To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.

        6. To study the impacts of Pharmaceutical care program on glycemic control in patients with
           Type-2 Diabetes Mellitus.

        7. To study the Drug utilization pattern in Type-2 Diabetes Mellitus in civil hospital
           Dhule.

        8. To compare the efficiency of Pharmaceutical care program and drug in patients with
           Type-2 Diabetes Mellitus.

        9. To study the Pharmaco-economic evaluation in Type-2 Diabetes Mellitus patient's.

       10. To increase the patient compliance and positive attitude of patients towards the
           diabetes disease by counseling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with
      Type-2 Diabetes Mellitus.

      To study the prevalence of Type2 diabetics cases in Dhule. To study the Assessment of
      different type of adverse drug reactions (ADRs). In Type2 diabetics.

      To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded: Fasting blood glucose measurements recorded (mg/dl).Postprandial bloodglucoseRecorded</measure>
    <time_frame>24 weeks</time_frame>
    <description>Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded fasting blood glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Quality of Life score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>DIABETES MELLITUS, TYPE 2</condition>
  <arm_group>
    <arm_group_label>PHARMACEUTICAL CARE programe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>without pharmaceutical care programe (control)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PHARMACEUTICAL CARE programe</intervention_name>
    <description>The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.</description>
    <arm_group_label>PHARMACEUTICAL CARE programe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Without PHARMACEUTICAL CARE programe</intervention_name>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Inclusion Criteria:

          -  Patients with type 2 diabetes mellitus of either

          -  Patients with HbA1c more than 7% and

          -  Patients with blood sugar level more than 140 mg / dl

        Exclusion Criteria:

          -  Patient with end stage kidney disease.

          -  Patient with heart failure.

          -  Patient with chronic Diabetes problem and orthopedic problem
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>tabrej aj mujawar, mpharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>muhs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tabrej Aj Mujawar</name>
      <address>
        <city>Dhule</city>
        <state>Maharashtra</state>
        <zip>424001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2015</study_first_submitted>
  <study_first_submitted_qc>May 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2015</study_first_posted>
  <last_update_submitted>November 3, 2015</last_update_submitted>
  <last_update_submitted_qc>November 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>R. C. Patel Institute of Pharmaceutical Education &amp; Research</investigator_affiliation>
    <investigator_full_name>TABREJ MUJAWAR</investigator_full_name>
    <investigator_title>tabrej mujawar mpharm Study principal investigator</investigator_title>
  </responsible_party>
  <keyword>pharmaceutical care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

